Presentation_Grau(Roche)_Miptec 2011_ ... - Cisbio Bioassays

More documents

Recommendations

Info

Introduction TagLite Results Outlook Sandra Grau, Roche Glycart AG 2
Introduction Antibody therapies ‣ Monoclonal antibodies represent a growing class of therapeutics with more than 20 molecules licenced for the treatment of cancer and chronic diseases. ‣ Major indications: oncology, infectious diseases and autoimmunity. ‣ Efficacy results from their specificity to the antigen target as well as the activation of effector functions. ‣ In oncology one relevant mechanism of action is antibody-mediated cellular cytotoxicity (ADCC): • This was shown for various antibody therapeutics such as rituximab (anti-CD20) and trastuzumab (anti-Her2). • The mechanism underlying ADCC is the binding of FcgRIIIa on natural killer cells (NK cells) to the Fc portion of an IgG and killing of the target cell Sandra Grau, Roche Glycart AG 3
Page 1: IgG core a-fucosylation and its imp
Page 5 and 6: Introduction Glycoengineering ‣ G
Page 7 and 8: Introduction Crystal structure of F
Page 9 and 10: Introduction Characterization of mo
Page 11 and 12: TagLite - results FcgRIIIaV158 and
Page 13 and 14: TagLite - results FcgRIIIa(F158)
Page 15 and 16: a-fuc increase a-fuc increase TagLi
Page 17 and 18: Introduction TagLite Results Outloo
Page 19 and 20: Acknowledgements Roche Glycart Pabl

Presentation_Grau(Roche)_Miptec 2011_ ... - Cisbio Bioassays

Create successful ePaper yourself

Delete template?

Save as template?